Pescovitz 2007.

Methods	Design: open‐label RCT Duration: not reported Follow up: 6 months
Participants	Setting: multicentre (6 centres) Country: USA Kidney transplant recipients aged 18 to 75 years able to take oral medications Number (group 1/group 2): 45 (30/15) Median age, range (years): group 1 (49.0, 21 to 70); group 2 (47.0, 28 to 64) Sex (M/F): group 1 (16/14); group 2 (12/3) Exclusions: HLA identical; PRA > 20%; HIV +ve; HepB surface antigen +ve; WBC < 2.5 x 109; platelets <100 x 109; Hb < 6 g/dL; hyperlipidaemia in previous year; African‐Americans GI disorders likely to impair absorption; previous cancers; previous treatment with daclizumab
Interventions	Treatment group 1 SRL: 15 mg/d for days 1 to 3; then 10 mg/day to 10 to 25 ng/mL at 2 months; maintenance 8 to 15 ng/mL Treatment group 2 CSA: administered according to centre practice Co‐interventions Daclizumab MMF: 2 g/d Prednisolone
Outcomes	Death (all causes) Graft loss censored for death Graft loss or death with a functioning graft Acute rejection CrCl SCr Malignancy Biochemical adverse effects
Notes	Comparison: TOR‐I versus CNI
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Enrolled 2:1 before transplant. No other information provided
Allocation concealment (selection bias)	Unclear risk	insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Primary outcomes BPAR, death, graft loss unlikely to be influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients accounted for
Selective reporting (reporting bias)	Low risk	Expected outcomes reported
Other bias	High risk	Sponsored by Roche